Regeneron Pharmaceuticals IncChange company Symbol lookupSelect an option...REGN Regeneron Pharmaceuticals IncLOTZ Carlotz IncTSLA Tesla IncINN Summit Hotel Properties IncNCNO nCino IncFISK Empire State Realty OP LPRMD Resmed IncBST BlackRock Science and Technology TrustMPW Medical Properties Trust IncUWHR Uwharrie Capital CorpGo
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.
|
|
|
|
| |
REGN's position in the Biotechnology industry
| Industry Peers | AMGN | GILD | INCY | UTHR | |
|---|---|---|---|---|---|
Summary | |||||
| Company Profile | Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's... | Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products... Go to AMGN summary | Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer... Go to GILD summary | Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutics. The Company also conducts commercial and clinical development... Go to INCY summary | United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and... Go to UTHR summary |
| 52-Week Change | VS. INDUSTRY | -13.94% | 0.96% | -26.03% | 20.45% |
| Market Cap | VS. INDUSTRY | $125.3B | $84.5B | $16.2B | $8.9B |
| Beta | VS. INDUSTRY | 0.6 | 0.4 | 0.7 | 0.6 |
| Dividend Yield | VS. INDUSTRY | 3.49% | 4.22% | -- | -- |
| P/E (TTM, GAAP) | VS. INDUSTRY | 22.92x | 11.53x | 30.44x | 20.13x |
| Data as of | |||||
Fundamentals | |||||
| Total Revenue (TTM) | VS. INDUSTRY | $25.8B | $27.5B | $2.9B | $1.7B |
| Profit Margin | VS. INDUSTRY | 21.77% | 26.81% | 18.35% | 27.94% |
| Earnings Growth (5 year, GAAP) | VS. INDUSTRY | 6.33% | -61.76% | -- | -1.93% |
| Revenue Growth (TTM) | VS. INDUSTRY | 3.12% | 18.73% | 18.58% | 17.43% |
| Data as of |
Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.